Enhanced Methods for the Use of 5'-Adenosine Diphosphate Ribose (ADPR)

Publication ID: 24-11857561_0001_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Methods for the Use of 5'-Adenosine Diphosphate Ribose (ADPR),” Published Technical Disclosure No. 24-11857561_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857561_0001_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,561.

Summary of the Inventive Concept

Improved methods and compositions for treating adenovirus-related diseases or conditions using 5'-adenosine diphosphate ribose (ADPR), addressing the limitations of existing treatments.

Background and Problem Solved

The original patent disclosed methods for using ADPR to treat adenovirus-related diseases or conditions, but had limitations in terms of efficacy, delivery, and side effects. The new inventive concept addresses these limitations by introducing novel systems, methods, and compositions that enhance the treatment of adenovirus-related diseases or conditions using ADPR.

Detailed Description of the Inventive Concept

The new inventive concept comprises four main aspects: (1) a system for treating adenovirus-related diseases or conditions using a topical administration device, (2) a method for enhancing the efficacy of ADPR by dividing the daily dose into multiple sub-doses, (3) a pharmaceutical composition that includes a penetration enhancer to facilitate delivery across epithelial or mucosal barriers, and (4) a system for monitoring the efficacy of ADPR using a biosensor. These aspects work together to provide a more effective and efficient treatment for adenovirus-related diseases or conditions.

Novelty and Inventive Step

The new inventive concept introduces novel systems, methods, and compositions that are not obvious from the original patent. The use of a topical administration device, divided daily doses, penetration enhancers, and biosensors for monitoring efficacy are all new and non-obvious features that improve the treatment of adenovirus-related diseases or conditions using ADPR.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include different types of administration devices, varying the frequency and timing of sub-doses, using different penetration enhancers, or incorporating additional components to enhance efficacy. These variations could be used to tailor the treatment to specific patient needs or to address different types of adenovirus-related diseases or conditions.

Potential Commercial Applications and Market

The enhanced methods and compositions for treating adenovirus-related diseases or conditions using ADPR have significant commercial potential in the pharmaceutical and biotechnology industries. The target market includes patients suffering from adenovirus-related diseases or conditions, as well as healthcare providers and researchers seeking more effective treatments.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical compositions and methods for treating viral infections, specifically focusing on adenosine diphosphate ribose (ADPR) delivery and therapeutic applications in adenovirus-related conditions

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or medical researcher with expertise in drug delivery systems, virology, and formulation techniques, holding at least a PhD or equivalent professional experience in pharmaceutical development

Obviousness Rationale

A person having ordinary skill in the art would recognize that the proposed variations represent predictable extensions of the source patent's core teachings about ADPR compositions. The PTD's modifications involve standard pharmaceutical engineering techniques such as dosing strategies, delivery mechanisms, and formulation enhancements that would be well within the capabilities of a skilled practitioner. The incremental improvements demonstrate routine optimization of an existing therapeutic approach rather than a non-obvious breakthrough.

Obvious Combinations & Variations

Source Patent Element

Topical pharmaceutical composition for treating microorganism infections in eye, respiratory, and gastrointestinal tracts

PTD Variation

Adding a specialized topical administration device to improve precise delivery of ADPR

Obviousness Reasoning

Selection and design of targeted delivery devices is a predictable solution for enhancing drug administration, representing a known technique in pharmaceutical engineering

Source Patent Element

Pharmaceutical composition containing dilithium ADPR

PTD Variation

Incorporating penetration enhancers to improve drug absorption across biological barriers

Obviousness Reasoning

Using penetration enhancers is a standard pharmaceutical formulation strategy for improving drug bioavailability, which would be an obvious approach to a skilled formulation scientist

Source Patent Element

Pharmaceutical composition for treating adenovirus-related conditions

PTD Variation

Dividing daily ADPR dose into multiple sub-doses to maintain consistent therapeutic concentration

Obviousness Reasoning

Dose fractionation is a well-known pharmacokinetic optimization technique for managing drug levels and reducing potential side effects

Source Patent Element

Pharmaceutical composition containing ADPR

PTD Variation

Implementing a biosensor system for monitoring drug concentration and treatment efficacy

Obviousness Reasoning

Real-time monitoring technologies are a predictable technological advancement for improving therapeutic management, representing an obvious extension of existing medical diagnostic approaches

Source Patent Element

Pharmaceutical composition for treating microorganism infections

PTD Variation

Combining ADPR with an anti-inflammatory agent to reduce potential treatment-related inflammation

Obviousness Reasoning

Co-administering complementary pharmaceutical agents to mitigate side effects is a standard medical practice that would be obvious to a skilled practitioner

35 U.S.C. § 103 Summary: Based on a comprehensive analysis of US Patent 11857561 and the corresponding Published Technical Disclosure, the proposed variations represent obvious modifications that would be readily conceived by a person having ordinary skill in the art. The incremental improvements in drug delivery, dosing strategies, and monitoring techniques do not rise to the level of non-obvious innovation, and therefore constitute prior art that would render similar claimed inventions obvious under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,857,561
Title	Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
Assignee(s)	Invirsa, Inc.